Gastrointestinal hypomotility and dysmotility reporting with GLP-1 receptor agonists and tirzepatide: a FAERS study of drug-specific patterns and onset

Glucagon-like peptide-1 receptor agonists and tirzepatide affect gastrointestinal motility, but drug-specific reporting and onset of events beyond common symptoms remain incompletely characterized. We examined these events to inform clinical assessment. We analyzed deduplicated FDA Adverse Event Reporting System reports from 2021Q1 to 2026Q1 in which one of six target drugs was designated the primary suspect. Study-defined preferred terms were grouped as core hypomotility/dysmotility events, supportive gastrointestinal symptoms, or exploratory aspiration-related events. We assessed reporting disproportionality, drug-specific patterns, serious outcomes, reporting-source sensitivity, and time to onset using treatment dates matched to the target drug. Among 243,269 target-drug reports, 6,252 involved core events. Core reporting was disproportionate (reporting odds ratio, 7.02; 95% confidence interval, 6.83–7.22), including reports of impaired gastric emptying, hypomotility, ileus, and intestinal obstruction. Four of six therapies showed positive core-group ROR signals, with drug-specific patterns across impaired gastric emptying, hypomotility, ileus, and obstruction. Serious outcomes were recorded in 91.3% of core reports. Among reports with valid target-drug-matched dates, median reported onset was 71.5 days for core events ( n = 1,986) and 2 days for supportive symptoms ( n = 8,335). Of 189 aspiration-related reports, 97 also contained core or supportive gastrointestinal terms; no positive aggregate aspiration signal was detected. Excluding lawyer-submitted reports reduced the 2026Q1 core reporting proportion, particularly for dulaglutide. Gastrointestinal motility-related reporting encompassed impaired gastric emptying, hypomotility, ileus, and obstruction, with variation across drugs and in recorded onset intervals. These findings highlight presentations that warrant clinical assessment during treatment and guide focused evaluation in clinical data.

Authors

Institutions

Publication Details

Journal
BMC Gastroenterology
Published
2026-11-16
DOI
https://doi.org/10.1186/s12876-026-05578-8
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Gastrointestinal hypomotility and dysmotility reporting with GLP-1 receptor agonists and tirzepatide: a FAERS study of drug-specific patterns and onset

Shengyong Yuan, Zunnan Huang, Xiaoling Liu, Xinghua Guo et al.
3 links
BMC Gastroenterology
Pharmacovigilance and Adverse Drug Reactions
article

Gastrointestinal hypomotility and dysmotility reporting with GLP-1 receptor agonists and tirzepatide: a FAERS study of drug-specific patterns and onset

Shengyong Yuan, Zunnan Huang, Xiaoling Liu, Xinghua Guo, Ruihui Ou
article en

Abstract

Glucagon-like peptide-1 receptor agonists and tirzepatide affect gastrointestinal motility, but drug-specific reporting and onset of events beyond common symptoms remain incompletely characterized. We examined these events to inform clinical assessment. We analyzed deduplicated FDA Adverse Event Reporting System reports from 2021Q1 to 2026Q1 in which one of six target drugs was designated the primary suspect. Study-defined preferred terms were grouped as core hypomotility/dysmotility events, supportive gastrointestinal symptoms, or exploratory aspiration-related events. We assessed reporting disproportionality, drug-specific patterns, serious outcomes, reporting-source sensitivity, and time to onset using treatment dates matched to the target drug. Among 243,269 target-drug reports, 6,252 involved core events. Core reporting was disproportionate (reporting odds ratio, 7.02; 95% confidence interval, 6.83–7.22), including reports of impaired gastric emptying, hypomotility, ileus, and intestinal obstruction. Four of six therapies showed positive core-group ROR signals, with drug-specific patterns across impaired gastric emptying, hypomotility, ileus, and obstruction. Serious outcomes were recorded in 91.3% of core reports. Among reports with valid target-drug-matched dates, median reported onset was 71.5 days for core events ( n = 1,986) and 2 days for supportive symptoms ( n = 8,335). Of 189 aspiration-related reports, 97 also contained core or supportive gastrointestinal terms; no positive aggregate aspiration signal was detected. Excluding lawyer-submitted reports reduced the 2026Q1 core reporting proportion, particularly for dulaglutide. Gastrointestinal motility-related reporting encompassed impaired gastric emptying, hypomotility, ileus, and obstruction, with variation across drugs and in recorded onset intervals. These findings highlight presentations that warrant clinical assessment during treatment and guide focused evaluation in clinical data.

BMC Gastroenterology
Guangdong Medical College (CN), Dongguan University of Technology (CN)
Good health and well-being
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon